nodes	percent_of_prediction	percent_of_DWPC	metapath
Ivacaftor—ABCB1—Dactinomycin—muscle cancer	0.216	0.218	CbGbCtD
Ivacaftor—ALB—Methotrexate—muscle cancer	0.154	0.155	CbGbCtD
Ivacaftor—ABCB1—Vincristine—muscle cancer	0.133	0.134	CbGbCtD
Ivacaftor—ABCB1—Etoposide—muscle cancer	0.122	0.123	CbGbCtD
Ivacaftor—ABCB1—Doxorubicin—muscle cancer	0.0832	0.0839	CbGbCtD
Ivacaftor—ABCB1—Methotrexate—muscle cancer	0.0806	0.0813	CbGbCtD
Ivacaftor—CYP3A4—Vincristine—muscle cancer	0.0797	0.0804	CbGbCtD
Ivacaftor—CYP3A4—Etoposide—muscle cancer	0.0731	0.0737	CbGbCtD
Ivacaftor—CYP3A4—Doxorubicin—muscle cancer	0.0498	0.0503	CbGbCtD
Ivacaftor—Bilirubin total increased—Doxorubicin—muscle cancer	0.000613	0.0733	CcSEcCtD
Ivacaftor—Mastitis—Doxorubicin—muscle cancer	0.000503	0.0602	CcSEcCtD
Ivacaftor—Musculoskeletal chest pain—Doxorubicin—muscle cancer	0.000317	0.0379	CcSEcCtD
Ivacaftor—Aspartate aminotransferase increased—Dactinomycin—muscle cancer	0.000214	0.0256	CcSEcCtD
Ivacaftor—Transaminases increased—Doxorubicin—muscle cancer	0.000202	0.0242	CcSEcCtD
Ivacaftor—Aspartate aminotransferase increased—Vincristine—muscle cancer	0.000191	0.0229	CcSEcCtD
Ivacaftor—Hyperaesthesia—Doxorubicin—muscle cancer	0.000157	0.0187	CcSEcCtD
Ivacaftor—Hepatic enzyme increased—Methotrexate—muscle cancer	0.00015	0.018	CcSEcCtD
Ivacaftor—Connective tissue disorder—Vincristine—muscle cancer	0.000144	0.0173	CcSEcCtD
Ivacaftor—Infestation NOS—Etoposide—muscle cancer	0.000133	0.0159	CcSEcCtD
Ivacaftor—Infestation—Etoposide—muscle cancer	0.000133	0.0159	CcSEcCtD
Ivacaftor—Mediastinal disorder—Vincristine—muscle cancer	0.000132	0.0158	CcSEcCtD
Ivacaftor—Blood bilirubin increased—Doxorubicin—muscle cancer	0.00013	0.0155	CcSEcCtD
Ivacaftor—Gynaecomastia—Methotrexate—muscle cancer	0.000127	0.0152	CcSEcCtD
Ivacaftor—Myalgia—Dactinomycin—muscle cancer	0.000122	0.0146	CcSEcCtD
Ivacaftor—Infection—Dactinomycin—muscle cancer	0.000116	0.0139	CcSEcCtD
Ivacaftor—Myalgia—Vincristine—muscle cancer	0.000109	0.013	CcSEcCtD
Ivacaftor—Mediastinal disorder—Etoposide—muscle cancer	0.000107	0.0128	CcSEcCtD
Ivacaftor—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.000106	0.0127	CcSEcCtD
Ivacaftor—Infection—Vincristine—muscle cancer	0.000104	0.0124	CcSEcCtD
Ivacaftor—Nervous system disorder—Vincristine—muscle cancer	0.000102	0.0122	CcSEcCtD
Ivacaftor—Gastrointestinal pain—Dactinomycin—muscle cancer	9.55e-05	0.0114	CcSEcCtD
Ivacaftor—Musculoskeletal discomfort—Vincristine—muscle cancer	9.51e-05	0.0114	CcSEcCtD
Ivacaftor—Breast disorder—Methotrexate—muscle cancer	9.31e-05	0.0111	CcSEcCtD
Ivacaftor—Abdominal pain—Dactinomycin—muscle cancer	9.24e-05	0.011	CcSEcCtD
Ivacaftor—Hypoglycaemia—Doxorubicin—muscle cancer	9.14e-05	0.0109	CcSEcCtD
Ivacaftor—Gastrointestinal disorder—Vincristine—muscle cancer	9.01e-05	0.0108	CcSEcCtD
Ivacaftor—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	8.76e-05	0.0105	CcSEcCtD
Ivacaftor—Gastrointestinal pain—Vincristine—muscle cancer	8.54e-05	0.0102	CcSEcCtD
Ivacaftor—Infection—Etoposide—muscle cancer	8.4e-05	0.01	CcSEcCtD
Ivacaftor—Upper respiratory tract infection—Methotrexate—muscle cancer	8.28e-05	0.0099	CcSEcCtD
Ivacaftor—Abdominal pain—Vincristine—muscle cancer	8.25e-05	0.00987	CcSEcCtD
Ivacaftor—Skin disorder—Etoposide—muscle cancer	8.21e-05	0.00983	CcSEcCtD
Ivacaftor—Breast disorder—Doxorubicin—muscle cancer	8.06e-05	0.00965	CcSEcCtD
Ivacaftor—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	8.03e-05	0.00961	CcSEcCtD
Ivacaftor—Diarrhoea—Dactinomycin—muscle cancer	7.99e-05	0.00956	CcSEcCtD
Ivacaftor—Nasopharyngitis—Doxorubicin—muscle cancer	7.98e-05	0.00955	CcSEcCtD
Ivacaftor—Infestation NOS—Methotrexate—muscle cancer	7.94e-05	0.0095	CcSEcCtD
Ivacaftor—Infestation—Methotrexate—muscle cancer	7.94e-05	0.0095	CcSEcCtD
Ivacaftor—Rash—Dactinomycin—muscle cancer	7.37e-05	0.00881	CcSEcCtD
Ivacaftor—Gastrointestinal disorder—Etoposide—muscle cancer	7.3e-05	0.00873	CcSEcCtD
Ivacaftor—Upper respiratory tract infection—Doxorubicin—muscle cancer	7.17e-05	0.00857	CcSEcCtD
Ivacaftor—Diarrhoea—Vincristine—muscle cancer	7.14e-05	0.00854	CcSEcCtD
Ivacaftor—Nausea—Dactinomycin—muscle cancer	6.94e-05	0.0083	CcSEcCtD
Ivacaftor—Gastrointestinal pain—Etoposide—muscle cancer	6.91e-05	0.00827	CcSEcCtD
Ivacaftor—Dizziness—Vincristine—muscle cancer	6.9e-05	0.00826	CcSEcCtD
Ivacaftor—Infestation NOS—Doxorubicin—muscle cancer	6.88e-05	0.00823	CcSEcCtD
Ivacaftor—Infestation—Doxorubicin—muscle cancer	6.88e-05	0.00823	CcSEcCtD
Ivacaftor—Abdominal pain—Etoposide—muscle cancer	6.68e-05	0.008	CcSEcCtD
Ivacaftor—Tinnitus—Methotrexate—muscle cancer	6.65e-05	0.00795	CcSEcCtD
Ivacaftor—Rash—Vincristine—muscle cancer	6.58e-05	0.00787	CcSEcCtD
Ivacaftor—Dermatitis—Vincristine—muscle cancer	6.58e-05	0.00787	CcSEcCtD
Ivacaftor—Headache—Vincristine—muscle cancer	6.54e-05	0.00782	CcSEcCtD
Ivacaftor—Mediastinal disorder—Methotrexate—muscle cancer	6.42e-05	0.00769	CcSEcCtD
Ivacaftor—Nausea—Vincristine—muscle cancer	6.2e-05	0.00742	CcSEcCtD
Ivacaftor—Rhinitis—Doxorubicin—muscle cancer	6.19e-05	0.0074	CcSEcCtD
Ivacaftor—Connective tissue disorder—Doxorubicin—muscle cancer	6.07e-05	0.00726	CcSEcCtD
Ivacaftor—Diarrhoea—Etoposide—muscle cancer	5.79e-05	0.00692	CcSEcCtD
Ivacaftor—Tinnitus—Doxorubicin—muscle cancer	5.76e-05	0.00689	CcSEcCtD
Ivacaftor—Dizziness—Etoposide—muscle cancer	5.59e-05	0.00669	CcSEcCtD
Ivacaftor—Mediastinal disorder—Doxorubicin—muscle cancer	5.56e-05	0.00666	CcSEcCtD
Ivacaftor—Rash—Etoposide—muscle cancer	5.33e-05	0.00638	CcSEcCtD
Ivacaftor—Dermatitis—Etoposide—muscle cancer	5.33e-05	0.00637	CcSEcCtD
Ivacaftor—Headache—Etoposide—muscle cancer	5.3e-05	0.00634	CcSEcCtD
Ivacaftor—Myalgia—Methotrexate—muscle cancer	5.28e-05	0.00632	CcSEcCtD
Ivacaftor—Arthralgia—Methotrexate—muscle cancer	5.28e-05	0.00632	CcSEcCtD
Ivacaftor—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	5.25e-05	0.00628	CcSEcCtD
Ivacaftor—Infection—Methotrexate—muscle cancer	5.03e-05	0.00602	CcSEcCtD
Ivacaftor—Nausea—Etoposide—muscle cancer	5.02e-05	0.00601	CcSEcCtD
Ivacaftor—Nervous system disorder—Methotrexate—muscle cancer	4.97e-05	0.00594	CcSEcCtD
Ivacaftor—Skin disorder—Methotrexate—muscle cancer	4.92e-05	0.00589	CcSEcCtD
Ivacaftor—Musculoskeletal discomfort—Methotrexate—muscle cancer	4.61e-05	0.00552	CcSEcCtD
Ivacaftor—Myalgia—Doxorubicin—muscle cancer	4.57e-05	0.00547	CcSEcCtD
Ivacaftor—Arthralgia—Doxorubicin—muscle cancer	4.57e-05	0.00547	CcSEcCtD
Ivacaftor—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	4.54e-05	0.00544	CcSEcCtD
Ivacaftor—Gastrointestinal disorder—Methotrexate—muscle cancer	4.37e-05	0.00523	CcSEcCtD
Ivacaftor—Infection—Doxorubicin—muscle cancer	4.36e-05	0.00521	CcSEcCtD
Ivacaftor—Nervous system disorder—Doxorubicin—muscle cancer	4.3e-05	0.00515	CcSEcCtD
Ivacaftor—Skin disorder—Doxorubicin—muscle cancer	4.26e-05	0.0051	CcSEcCtD
Ivacaftor—Gastrointestinal pain—Methotrexate—muscle cancer	4.14e-05	0.00495	CcSEcCtD
Ivacaftor—Abdominal pain—Methotrexate—muscle cancer	4e-05	0.00479	CcSEcCtD
Ivacaftor—Musculoskeletal discomfort—Doxorubicin—muscle cancer	4e-05	0.00478	CcSEcCtD
Ivacaftor—Gastrointestinal disorder—Doxorubicin—muscle cancer	3.79e-05	0.00453	CcSEcCtD
Ivacaftor—Gastrointestinal pain—Doxorubicin—muscle cancer	3.59e-05	0.00429	CcSEcCtD
Ivacaftor—Abdominal pain—Doxorubicin—muscle cancer	3.47e-05	0.00415	CcSEcCtD
Ivacaftor—Diarrhoea—Methotrexate—muscle cancer	3.47e-05	0.00415	CcSEcCtD
Ivacaftor—Dizziness—Methotrexate—muscle cancer	3.35e-05	0.00401	CcSEcCtD
Ivacaftor—Rash—Methotrexate—muscle cancer	3.19e-05	0.00382	CcSEcCtD
Ivacaftor—Dermatitis—Methotrexate—muscle cancer	3.19e-05	0.00382	CcSEcCtD
Ivacaftor—Headache—Methotrexate—muscle cancer	3.17e-05	0.0038	CcSEcCtD
Ivacaftor—Nausea—Methotrexate—muscle cancer	3.01e-05	0.0036	CcSEcCtD
Ivacaftor—Diarrhoea—Doxorubicin—muscle cancer	3e-05	0.00359	CcSEcCtD
Ivacaftor—Dizziness—Doxorubicin—muscle cancer	2.9e-05	0.00347	CcSEcCtD
Ivacaftor—Rash—Doxorubicin—muscle cancer	2.77e-05	0.00331	CcSEcCtD
Ivacaftor—Dermatitis—Doxorubicin—muscle cancer	2.76e-05	0.0033	CcSEcCtD
Ivacaftor—Headache—Doxorubicin—muscle cancer	2.75e-05	0.00329	CcSEcCtD
Ivacaftor—Nausea—Doxorubicin—muscle cancer	2.6e-05	0.00312	CcSEcCtD
